MERIDEN, CT, United States

Time filter

Source Type

Dublin, April 18, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast, 2016 to 2022" drug pipelines to their offering. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants. Further, prudent analysis has been done on the competitor's part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market. Seven Major Markets(7MM) covered in the report are as follows: 1. United States 2. United Kingdom 3. France 4. Italy 5. Spain 6. Germany 7. Japan Major and Promising Vaccines covered in the report are as follows: 1. Fluzone High-Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN-100 11. M-001 12. VAX-2012Q 13. TAK-850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Seasonal Influenza Vaccine Report is segmented into 10 points: 1: Introduction with Executive Summary 2: Forecasts data for the seasonal influenza vaccine market in the top seven countries. This point is divided into 4 segments. - Overall seasonal influenza vaccine market data from 2010 to 2022 - Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022 - Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022 - Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022 3: Key market drivers and barriers in the seasonal influenza vaccine market 4: Detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage 5: Detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination 6: Information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan 7: Key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals 8: Detailed pipeline influenza vaccines in various companies' pipelines with clinical development and early stage development vaccines 9: Detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase 10: Information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jc66pd/seasonal


News Article | December 28, 2016
Site: marketersmedia.com

The analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020. According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose. Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. For more information or any query mail at sales@wiseguyreports.com The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines. The market is divided into the following segments based on geography: • Americas • APAC • Europe The report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Other prominent vendors • Abbott • AstraZeneca • Bavarian Nordic • Baxter • Bharat Biotech • Bharat Immunologicals and Biologicals • bioCSL • Bio Med • Crucell • Dynavax Technologies • Indian Immunologicals • Janssen Pharmaceuticals • Kaketsuken • LG Life Sciences • Mitsubishi Tanabe Pharma • Lupin • Nuron • Novartis • Protein Sciences Corporation • Panacea Biotec • Roche • Serum Institute of India • Shenzhen Kangtai Biological Products • Sinovac Biotech • S K Chemicals • Takeda Pharmaceutical • Valeant Pharmaceuticals • Zydus Cadila Market driver • Growing awareness about vaccination and immunization programs • For a full, detailed list, view our report Market trend • Increase in strategic alliance and M&A • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Influenza Vaccines Market in Top 5 European Countries to 2022 - Market Size, Development and Forecasts" report to their offering. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. Prudent analysis has been done on the competitor's part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline (GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market. Major and Promising Vaccines covered in the report are as follows: Key Companies Covered in the Report are as follows: For more information about this report visit http://www.researchandmarkets.com/research/n7tsqb/influenza


Research and Markets has announced the addition of the "Influenza Vaccines Market in Top 5 European Countries to 2022 - Market Size, Development and Forecasts" report to their offering. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. Prudent analysis has been done on the competitor's part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market. Major and Promising Vaccines covered in the report are as follows: 1. Fluzone High-Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN-100 11. M-001 12. VAX-2012Q 13. TAK - 850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Key Companies Covered in the Report are as follows: 1. Sanofi Pasteur 2. GlaxoSmithKline(GSK) 3. Seqirus 4. AstraZenecca 5. Protein Sciences Corporation 6. Novavax 7. Daiichi-Sankyo 8. Mitsubishi Tanabe Pharma 9. BiondVax Pharmaceuticals Ltd 10. VaxInnate Key Topics Covered: 1. Executive Summary 2. Influenza Vaccine Market in Top 5 European Countries - Market Overview 3. Influenza Vaccine Market Drivers and Barriers 4. Influenza Vaccine Market in Top 5 European Countries - Geographical Landscape 5. European Union Influenza Vaccine Market - Regulatory Landscape 6. Market Dynamics - Mergers, Acquisitions, Key Agreements & Collaborations 7. Influenza Vaccine - Pipeline Assessment 8. Influenza Vaccine - Clinical Trials Assessment by Phase and Trial Status 9. Key Companies Analysis For more information about this report visit http://www.researchandmarkets.com/research/hcj3f7/influenza Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716


Cox M.M.J.,Protein Sciences Corporation
Vaccine | Year: 2012

The baculovirus-insect cell expression system is a well known tool for the production of complex proteins. The technology is also used for commercial manufacture of various veterinary and human vaccines. This review paper provides an overview of how this technology can be applied to produce a multitude of vaccine candidates. The key advantage of this recombinant protein manufacturing platform is that a universal "plug and play" process may be used for producing a broad range of protein-based prophylactic and therapeutic vaccines for both human and veterinary use while offering the potential for low manufacturing costs. Large scale mammalian cell culture facilities previously established for the manufacturing of monoclonal antibodies that have now become obsolete due to yield improvement could be deployed for the manufacturing of these vaccines. Alternatively, manufacturing capacity could be established in geographic regions that do not have any vaccine production capability. Dependent on health care priorities, different vaccines could be manufactured while maintaining the ability to rapidly convert to producing pandemic influenza vaccine when the need arises. © 2012 Elsevier Ltd.


Patent
Protein Sciences Corporation | Date: 2013-03-15

The present invention relates to methods of improving the stability and maintaining the potency of recombinant hemagglutinin formulations, in particular, recombinant influenza hemagglutinin (rHA). In particular, Applicants have shown that the stability of rHA formulations may be significantly improved by mutating cysteine residues or by formulating with a reducing agent and sodium citrate.


Grant
Agency: Department of Defense | Branch: Army | Program: SBIR | Phase: Phase I | Award Amount: 100.00K | Year: 2015

In this proposal, Protein Sciences Corporation proposes to develop a bivalent, recombinant protein based adenovirus vaccine to protect against serotypes 4 and 7, based on our proprietary platform technology of baculovirus expression vector system (BEVS) and insect cells. We propose the hexon protein as the target antigen as it is considered the primary target for neutralizing antibodies generated against adenovirus, and protection from adenovirus disease is associated with the presence of serotype specific serum neutralizing antibodies. The use of recombinant baculovirus to express foreign proteins in insect cells has been well characterized, and has matured into a commercial manufacturing technology. This technology will allow rapid incorporation of additional serotypes if the need arises. The fundamental high level objective of Phase I is to demonstrate the feasibility of expression and purification of the hexon proteins based on the BEVS and insect cell platform technology, and to provide preliminary stability assessment on the candidate product. The resulting proof-of-concept data should support the future objectives in Phase II for pilot scale process development, immunogenicity studies in small animals, toxicology study, and other preparation activities related to filing an Investigational New Drug (IND) application with the FDA for Phase I clinical trial.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.20M | Year: 2014

DESCRIPTION provided by applicant Lung cancer is the leading cause of cancer death in the United States and is responsible for more deaths each year than breast prostate colon hepatic renal and skin cancers combined Viewed in economic terms in the United States the value of life lost from lung cancer deaths in the year was more than $ billion which is estimated to rise to more than $ billion in Because of the immense health care and economic burden imposed by lung cancer new therapy strategies that improve patient outcomes will lead to very a significant impact Collaborators at Chesapeake PERL Inc C PERL and UCLA Laboratory of Leonard Rome have identified and characterized a unique nanoparticle structure called a vault that is highly stable and found ubiquitously in all higher eukaryotes The vault shell is entirely composed of multiple copies of a single protein called Major Vault Protein MVP MVP can be readily engineered to permit attachment of other agents including promising cancer therapeutics like the chemokine CCL CCL is a lymphoid chemokine that is chemoattractant for mature dendritic cells DCs and naive and memory T cells Preclinical studies in a lung cancer animal model have demonstrated that intratumoral administration of CCL gene modified dendritic cells led to tumor eradication Vaults have been expressed at Chesapeake PERL Inc C PERL to very high levels using the PERLXpress protein expression platform The unique and powerful system uses recombinant baculovirus expression in whole insects in an automated platform to generate high protein yields cost effectively MVP and CCL fused to a vault packaging peptide called INT are readily expressed and correctly assembled to form CCL Vault nanoparticles The particle has been shown to slowly release its chemokine payload over several days Hundreds of milligrams of highly purified CCL Vaults can be readily prepared and stably stored in a lyophilized state for future therapeutic evaluation and testing Continued development proposed in this Phase II application will support advanced development pre clinical safety evaluation including toxicology efficacy and formulation leading to IND preparation to support future GCMP product manufacture Intratumoral administration of recombinant CCL vaults derived from baculovirus infection of whole insects will be tested in a preclinical animal model for destruction of tumors The CCL Vault is proposed to circumvent autologous DC preparation minimize batch to batch variability and allow for comparability and standardization so that the particle can be used as an off the shelf reagent for advanced non small cell lung cancer NSCLC PUBLIC HEALTH RELEVANCE This project is relevant to treatment of common causes of death and disability due to lung cancer The research will support continued development of a candidate therapy using a recombinant version of naturally occurring human vault protein in combination with CCL antitumor agent The combination technologies may result in a drug that targets lung cancer demonstrating a large scale low cost reproducible therapy This is a potentially disruptive approach that can revolutionize the lung cancer field and may be applied to other cancers


Patent
Protein Sciences Corporation | Date: 2011-10-12

A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HAO), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus chitinase signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed for the purification of rHA proteins from A sub-types and B type influenza viruses.


MERIDEN, Conn., Feb. 22, 2017 /PRNewswire/ -- Protein Sciences Corporation, a leading vaccine development company and maker of Flublok® Influenza Vaccine, announced today that they donated 45,000 doses of Flublok to The Partnership for Influenza Vaccine Introduction (PIVI) and the...

Loading Protein Sciences Corporation collaborators
Loading Protein Sciences Corporation collaborators